To announce the availability of all the products in the SENG range on the Filipino market - SUISENG®, RHINISENG®, ERYSENG® PARVO and ERYSENG® PARVO/LEPTO - HIPRA organized an event on 25th October last in the prestigious hotel Edsa Shangri-La in Manila.
Entitled "HIPRAMUNE® G: creating immunity for the future", HIPRA brought together 115 professionals from the swine sector who, under the guidance of experts Young. S Lyoo (Professor, University of Konkuk, Korea), Romeo E. Sánchez (Professor, Los Baños University, Philippines), Alberto Morillo (International Consultant, Tests and Trials, Spain) and Alberto Stephano (International Consultant, Stephano Consultores SC, Mexico) explored the past, present and future of swine production in Asia in an interesting interactive discussion in which there was a high level of public participation.
After the discussion, Joseph Emil Rubico (Technical and Marketing Manager, HIPRA Philippines) presented HIPRAMUNE® G, highlighting the potency of this adjuvant, and then Ming Hsun Wu (Regional Technical and Marketing Manager, HIPRA) provided an update on the most recent experiences with SUISENG®.
Alba Martos (Corporate Product Manager, HIPRA) was responsible for presenting RHINISENG®, the only vaccine against progressive and non-progressive atrophic rhinitis, together with the exclusive programme for its diagnosis and control.
To conclude the day, Agustí Camprodon (Corporate Brand Manager, HIPRA) presented the new trivalent vaccine ERYSENG® PARVO/LEPTO, a unique and innovative vaccine that will revolutionise the market thanks to its perfect balance between safety and efficacy.
With the launch of ERYSENG® PARVO/LEPTO and RHINISENG®, HIPRA consolidates the SENG range as “the most modern and complete range of vaccines for breeders”, and reinforces its commitment to continue growing as the Reference in Prevention for Animal Health.
